| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Common Stock | Options Exercise | $1.69M | +19.4K | +32.83% | $87.10 | 78.6K | Feb 2, 2024 | Direct | |
| transaction | MRK | Common Stock | Sale | -$6.28M | -49.5K | -63.01% | $126.97 | 29.1K | Feb 2, 2024 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Stock Option (Right to Buy) | Options Exercise | $0 | -19.4K | -33.33% | $0.00 | 38.8K | Feb 2, 2024 | Common Stock | 19.4K | $87.10 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.8650 to $127.3000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F2 | Holdings include shares acquired in dividend reinvestment transactions. |
| F3 | The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. |